ArticleQuantitative imaging in medicine and surgery2026
The association of neutrophil-lymphocyte ratio with stroke recurrence in patients with symptomatic nonacute atherosclerotic internal carotid artery occlusion.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerotic internal carotid artery occlusion (AICAO) is associated with a high risk of stroke recurrence despite standard medical therapy. This study aimed to evaluate the predictive value of the neutrophil-lymphocyte ratio (NLR), an accessible marker of systemic inflammation, for identifying patients at higher risk of recurrent stroke. Methods: This retrospective study enrolled 136 patients with AICAO, whose NLR data were collected. Recurrent stroke was evaluated via clinical and vascular imaging follow-up. Receiver operating characteristic (ROC) analysis was performed to determine the optimal NLR cutoff value. The value of NLR in predicting stroke recurrence was determined via a Cox regression model. Results: Of the 281 initially screened patients, 136 met the study's inclusion criteria (age 62±10 years; 68% male). Among the patients, 17 (12.5%) experienced ipsilateral stroke (1-year rate, 8.8%; 2-year rate, 12.5%). The median baseline NLR was higher in patients with recurrence [3.38, interquartile range (IQR), 2.20-4.95] than in those without recurrence (2.39, IQR, 1.82-3.02) (Mann-Whitney P=0.007). The ROC analysis indicated an optimal NLR cutoff of 3.36 [area under the curve (AUC) =0.703; 95% confidence interval (CI): 0.559-0.847; P=0.007; sensitivity =0.59; specificity =0.82]. Patients were stratified into NLR-high (>3.36; n=31) and NLR-low (≤3.36; n=105) groups, with the 1-year stroke rates being 22.5% (7/31) and 5.7% (6/105), respectively, with an absolute risk difference of 16.8% (95% CI: 3.4-30.2%). In the Kaplan-Meier analysis, the log-rank P value was 0.039. In the univariate Cox analysis, an NLR >3.36 yielded a hazard ratio (HR) of 3.83 for stroke recurrence (95% CI: 1.48-9.94; P=0.006). In the multivariable Cox analysis, an NLR >3.36 remained independently associated with recurrence (HR 4.17, 95% CI: 1.59-10.91; P=0.004). When NLR was modelled as a continuous log-transformed variable, each 1-unit increase yielded an HR of 1.99 (95% CI: 1.49-2.66; P<0.001). Conclusions: In symptomatic nonacute patients with AICAO, NLR is a predictor for recurrent stroke under standard medical treatment. Moreover, an NLR >3.36 is associated with a higher risk of stroke recurrence, and intensive surveillance in high-risk patients with this marker may be necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.